ATE437641T1 - Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis - Google Patents

Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis

Info

Publication number
ATE437641T1
ATE437641T1 AT04752432T AT04752432T ATE437641T1 AT E437641 T1 ATE437641 T1 AT E437641T1 AT 04752432 T AT04752432 T AT 04752432T AT 04752432 T AT04752432 T AT 04752432T AT E437641 T1 ATE437641 T1 AT E437641T1
Authority
AT
Austria
Prior art keywords
amyloid
microgliosis
reducing
animals
neurotoxicity
Prior art date
Application number
AT04752432T
Other languages
English (en)
Inventor
Michael Mullan
Daniel Paris
Original Assignee
Roskamp Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE437641(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roskamp Res Llc filed Critical Roskamp Res Llc
Application granted granted Critical
Publication of ATE437641T1 publication Critical patent/ATE437641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04752432T 2003-05-15 2004-05-17 Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis ATE437641T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47069403P 2003-05-15 2003-05-15
PCT/US2004/015417 WO2004110354A2 (en) 2003-05-15 2004-05-17 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis

Publications (1)

Publication Number Publication Date
ATE437641T1 true ATE437641T1 (de) 2009-08-15

Family

ID=33551420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752432T ATE437641T1 (de) 2003-05-15 2004-05-17 Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis

Country Status (10)

Country Link
US (1) US7732467B2 (de)
EP (1) EP1628663B1 (de)
JP (1) JP4971794B2 (de)
CN (1) CN100444840C (de)
AT (1) ATE437641T1 (de)
CA (1) CA2525970C (de)
DE (1) DE602004022284D1 (de)
DK (1) DK1628663T3 (de)
ES (1) ES2334029T3 (de)
WO (1) WO2004110354A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858325A4 (de) * 2005-01-07 2010-06-30 Roskamp Res Llc Verbindungen zur hemmung der beta-amyloidproduktion und verfahren zum identifizieren dieser verbindungen
WO2006109164A2 (en) * 2005-04-15 2006-10-19 Research & Innovation Soc. Coop. A R.L. A method for preventing, delaying or reverting abnormal amyloid deposition
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
EP2120557A4 (de) * 2006-12-08 2010-02-10 Roskamp Res Llc Polyhydrochinolinverbindungen und dihydropyridinverbindungen zur hemmung der beta-amyloid-produktion
US8709394B2 (en) * 2007-09-28 2014-04-29 Ndsu Research Foundation Antimicrobial polysiloxane materials containing metal species
CN101883564B (zh) * 2007-10-05 2013-10-16 阿尔茨海默病学会美国公司 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer
CA2761298A1 (en) * 2009-05-15 2010-11-18 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
EP2311823A1 (de) * 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridinverbindungen zur Behandlung von Krankheiten im Zusammenhang mit Amyloidproteinen oder zur Behandlung von Augenkrankheiten
KR20140128229A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) * 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンa物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) * 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
DE3877630T2 (de) 1987-06-12 1993-06-03 American Cyanamid Co Transkutane verabreichung von pharmazeutika.
US5114946A (en) * 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) * 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
DE3871343D1 (de) 1987-11-25 1992-06-25 American Cyanamid Co System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridin-calciumantagonisten.
US5160734A (en) * 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
AU5419690A (en) * 1989-03-31 1990-11-05 Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JPH03117658A (ja) 1989-09-29 1991-05-20 Mazda Motor Corp 外燃式ロータリピストンエンジン
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
EP0557290A1 (de) 1990-08-23 1993-09-01 The Children's Medical Center Corporation Behandlung von aids-assoziierter dementia, myelopathie, peripherer neuropathie und sehverlust
WO1993005770A1 (fr) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation a longue duree d'action
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンa物質含有易溶性固体分散体の製造法
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CA2252962A1 (en) * 1996-04-26 1997-11-06 Fujisawa Pharmaceutical Co., Ltd. Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
US6271259B1 (en) * 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
EP1085890A1 (de) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Neuartige natriumkanal-medikamente und deren verwendungen
JP2002517440A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規カルシウムチャンネル薬物および用途
KR20040078140A (ko) 1998-07-10 2004-09-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
WO2001064250A1 (en) 2000-03-03 2001-09-07 Fujisawa Pharmaceutical Co., Ltd. Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
BR0109991A (pt) 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
ATE357257T1 (de) * 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
AU2002227957A1 (en) * 2000-12-19 2002-07-01 Merck Patent Gmbh Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
BR0115995A (pt) * 2000-12-19 2004-01-13 Merck Patent Gmbh Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
US7083642B2 (en) * 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
WO2002096415A2 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
KR20100137026A (ko) 2002-05-17 2010-12-29 노파르티스 아게 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는 약제학적 조성물
TW200306799A (en) 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法

Also Published As

Publication number Publication date
EP1628663A2 (de) 2006-03-01
CN1809352A (zh) 2006-07-26
EP1628663B1 (de) 2009-07-29
US7732467B2 (en) 2010-06-08
EP1628663A4 (de) 2006-05-24
WO2004110354A2 (en) 2004-12-23
DE602004022284D1 (de) 2009-09-10
US20050009885A1 (en) 2005-01-13
JP4971794B2 (ja) 2012-07-11
DK1628663T3 (da) 2010-03-08
WO2004110354A3 (en) 2005-02-10
CA2525970C (en) 2011-03-22
CA2525970A1 (en) 2004-12-23
JP2007501277A (ja) 2007-01-25
CN100444840C (zh) 2008-12-24
HK1092358A1 (en) 2007-02-09
ES2334029T3 (es) 2010-03-04

Similar Documents

Publication Publication Date Title
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
EP0792156A4 (de) Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
PH12021553223A1 (en) IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
PH12021553232A1 (en) 2h-indazole derivatives and their use in the treatment of disease
DE602004024565D1 (de) Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
DE602004022284D1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
DE60312505D1 (de) Injektion aus ixeris sonchifolia zur behandlung von kardiozerebralen gefässerkrankungen und funduserkrankungen sowie herstellungsverfahren dafür
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
DE602005008417D1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
IL176453A0 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
Estrada et al. Transcranial magnetic stimulation on rodent models
DE60131100D1 (de) Verfahren zur behandlung bestimmter augenkrankheiten
SE0004455D0 (sv) Method for neuron regeneration in the central nervous system

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties